Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection

Dima Dandachi, Bich N. Dang, Brandon Lucari, Susan Swindells, Thomas P. Giordano

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The study evaluates the acceptability and preferences for long-acting antiretroviral therapy (LA-ART) among a diverse cohort of people with HIV infection (PWH). It consists of a self-administered survey and chart review of PWH presenting to an HIV clinic in Houston, Texas, between February and June 2018; 374 participants were included; 61% indicated that they were likely or very likely to use LA-ART formulations. When asked about preference, 41% preferred pills, 40% preferred injections, and 18% preferred an implant. The most common benefit reported was eliminating the need to remember taking daily HIV pills (74%); 43% were worried that LA-ART will not be as effective as pills. Participants with a college degree, men who have sex with men, and ART-experienced were more willing to use LA-ART. Participants who reported poor or fair health, or who screened positive for depression or anxiety were significantly less willing to use LA-ART. The likelihood of using LA-ART did not correlate with self-reported adherence and HIV suppression. Patients with difficulty scheduling and attending clinic visits preferred injections and implant over pills. Most participants indicated a willingness to use new LA ART formulations. However, 41% still prefers pills, and those more interested in LA-ART were not less adherent.

Original languageEnglish (US)
Pages (from-to)801-809
Number of pages9
JournalAIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
Issue number6
StatePublished - 2021


  • HIV
  • Long-acting antiretrovirals
  • acceptability
  • attitude
  • implants
  • survey

ASJC Scopus subject areas

  • Health(social science)
  • Social Psychology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection'. Together they form a unique fingerprint.

Cite this